?ECONOMIC IMPACT OF PET-18FLUTEMETAMOL GUIDED TREATMENT ALLOCATION IN THE DIAGNOSIS AND MANAGEMENT OF ALZHEIMER DISEASE. A BUDGET IMPACT MODEL FOR EUROPEAN PAYERS...
Author(s)
Anna Tokarz, MSc1, Montserrat Chivite, MSc2, Emilija Veljanoska, MSc3, Barbara Mascialino, MSc, PhD4, Arturo Cabra, BS, MSc5.
1Fortrea, Warsaw, Poland, 2GE Healthcare, Madrid, Spain, 3Fortrea, Munich, Germany, 4Fortrea, Recco, Italy, 5GE HealthCare, Miami, FL, USA.
1Fortrea, Warsaw, Poland, 2GE Healthcare, Madrid, Spain, 3Fortrea, Munich, Germany, 4Fortrea, Recco, Italy, 5GE HealthCare, Miami, FL, USA.
OBJECTIVES: Alzheimer’s Disease (AD) affects more than 10 million patients in Europe. From payer perspective, the correct diagnostic and management of these patients is paramount. The study aimed to (i) estimate the budget impact of adopting ¹⁸F-flutemetamol PET for AD diagnosis and treatment planning in Italy, Spain, France, Germany, and Netherlands, and (ii) evaluate the risk of potential misallocation of patients to inappropriate treatments in the context of emerging amyloid-targeting therapies (ATTs).
METHODS: A budget impact model was developed to simulate diagnostic and treatment outcomes over a five-year horizon, from the healthcare payers’ perspective. Eligible target population was estimated using country-specific demographics and incidence-rates for “AD” and “Mild Cognitive Impairment”. Diagnostic strategies were compared across scenarios, including ¹⁸F-flutemetamol PET with quantification, cerebrospinal fluid testing, and emerging blood-based biomarkers modelled as a screening tool. Considering the recent approval of ATTs by the European Medicines Agency (EMA), treatment costs were estimated using international price benchmarks converted to local currencies. Monitoring requirements for Alzheimer’s disease followed EMA guidance and were costed using country-specific tariffs.
RESULTS: Across all countries, results suggest that implementing ¹⁸F-flutemetamol PET with quantification could reduce the proportion of patients incorrectly receiving ATTs by approximately 30% and decrease those missing appropriate therapy by about 39%. Additionally, the proportion of patients requiring confirmatory testing for AD diagnosis was lowered. The use of ¹⁸F-flutemetamol PET was estimated to increase budget impact, ranging from around €57 million in the Netherlands to €932 million in Germany over 5 years.
CONCLUSIONS: The budget impact of adopting ¹⁸F-flutemetamol PET as the primary diagnostic modality is projected to be modest. Given the emergence of ATTs and their substantial costs, accurate identification of appropriate patients becomes critical from a payer perspective. ¹⁸F-flutemetamol PET remains the single diagnostic modality that may improve treatment allocation for patients, which is vital considering Europe’s rapidly ageing population.
METHODS: A budget impact model was developed to simulate diagnostic and treatment outcomes over a five-year horizon, from the healthcare payers’ perspective. Eligible target population was estimated using country-specific demographics and incidence-rates for “AD” and “Mild Cognitive Impairment”. Diagnostic strategies were compared across scenarios, including ¹⁸F-flutemetamol PET with quantification, cerebrospinal fluid testing, and emerging blood-based biomarkers modelled as a screening tool. Considering the recent approval of ATTs by the European Medicines Agency (EMA), treatment costs were estimated using international price benchmarks converted to local currencies. Monitoring requirements for Alzheimer’s disease followed EMA guidance and were costed using country-specific tariffs.
RESULTS: Across all countries, results suggest that implementing ¹⁸F-flutemetamol PET with quantification could reduce the proportion of patients incorrectly receiving ATTs by approximately 30% and decrease those missing appropriate therapy by about 39%. Additionally, the proportion of patients requiring confirmatory testing for AD diagnosis was lowered. The use of ¹⁸F-flutemetamol PET was estimated to increase budget impact, ranging from around €57 million in the Netherlands to €932 million in Germany over 5 years.
CONCLUSIONS: The budget impact of adopting ¹⁸F-flutemetamol PET as the primary diagnostic modality is projected to be modest. Given the emergence of ATTs and their substantial costs, accurate identification of appropriate patients becomes critical from a payer perspective. ¹⁸F-flutemetamol PET remains the single diagnostic modality that may improve treatment allocation for patients, which is vital considering Europe’s rapidly ageing population.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE30
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
SDC: Neurological Disorders